Participant flow

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer · Source last updated 2024-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT Gemcitabine: Gemcitabine will be administered on days 1, 8, 15 every 28 days TT vaccine booster: One human TT childhood vaccine booster will be administered on day 8

   id

   FG000

   title

   Gemcitabine With TT Vaccine Booster

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Patients diagnosed with PDAC will be treated with Gemcitabine as is standard of care on days 1, 8, 15 every 28 days. On day 8 one booster with the human TT childhood vaccine will be administered. Blood will be drawn before each Gemcitabine treatment. On day 8, TT booster will be administered immediately after blood draw but at least 2 hours before Gemcitabine treatment. Patients who withdraw on or before Day 8 (before TT treatment) will not be included in data analysis.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice